Browsing by Author "Porta, Camillo"
Now showing items 1-5 of 5
-
Cabozantinib combination therapy for the treatment of solid tumors: a systematic review
Castellano, Daniel; Apolo, Andrea; Porta, Camillo; Viteri, Santiago; Rodriguez-Antona, Cristina; Capdevila Castillon, Jaume (SAGE Publications, 2022) -
Cabozantinib for the treatment of solid tumors: a systematic review
Maroto, P.; Apolo, Andrea B.; Viteri Ramirez, Santiago; Martin, Lidia; Castellano, D.; Capdevila Castillon, Jaume; Porta, Camillo; Rodriguez-Antona, Cristina (SAGE Publications, 2022-07-13) -
Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma
Geynisman, Daniel M.; Burotto, Mauricio; Suárez Rodríguez, Cristina; Bourlon, Maria T.; Porta, Camillo; McGregor, Bradley (Oxford University Press, 2023-01) -
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy
Choueiri, T.; Suárez Rodríguez, Cristina; Hainsworth, John; Voog, Eric; Duran, Ignacio; Porta, Camillo (Oxford University Press, 2022-12) -
Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
Geynisman, Daniel M.; Burotto, Mauricio; Suárez Rodríguez, Cristina; Bourlon, Maria T.; Huo, Stephen; Porta, Camillo (Springer, 2022-07)